Human pharmacpkinetics of low molecular weight heparins

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 3, 1999, Pages 57-61

  Cornelli, Umberto ^a,b   Fareed, Jawed ^a,b  

^a Cornelli Consulting SAS ^*  (Italy)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Low molecular weight heparin; Pharmacodynamics; Pharmacokinetics

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

AREA UNDER THE CURVE; BIOEQUIVALENCE; COMPARTMENT MODEL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG POTENCY; HUMAN; MEAN RESIDENCE TIME; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOSIS;

ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD COAGULATION; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS;

EID: 0032743494     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. Philadelphia: Lea & Febiger; 1994:17-28
2. Fareed J, Jeske \V, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low molecular weight heparin preparations the same? Semin Thromb Hemost 1996;22:77-91
3. Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin. Acta Med Scan 1963;173:619-630
4. Hirsh J. Optimal therapeutic ranges from unfractioned heparin and low molecular weight heparins. In: Verstrate M, Fuster V, eds. Thrombosis in Cardiovascular Disorders. Philadelphia: Saunders; 1992:147-160
5. de Swart CAM, Nijmeyer B, Andersson LO, et al. Elimination of high affinity heparin fractions and their anticoagulant and lipase activity. Blood 1984;63:842-846
6. Nishiyama M, Matsubara Y, Ikeda S, et al. Studies on methabolic fate of low molecular weight heparin (FR-860): I. Metabolic fate in rats. lyakuhin Kenkyu 1989:20:1056-1079
7. Laforest MD, Colas Linhart N, Guiraud-Vitaux F, et al. Pharmacokinetics and distribution of technetium 99m labelled standard heparin and low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers. Br J Haematol 1991;77:201-208
8. 99mTc) heparin and low molecular weight heparin fractions CY 216, CY 222 in patients with uncomplicated myocardial infarction. Folia Haematol (Leipz) 1988:115:661-668
9. Jacques LB, Wice SM, Hiebert LM. Détermination of absolute amounts of heparin and dextran sulfate in plasma in microgram quantities. J Lab Clin Med 1990;! 15:422-432
10. Emanuele RM, Farced J. The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987;48:591-596
11. Bara L, Mardiguian J, Samama M. In vitro effect on Heptest® of low molecular weight heparin fractons and preparations with various anti-IIa and anti-Xa activities. Thromb Res 1990;57: 585-592
12. Kristensen HI, Ostergaard D, Nordsang O, et al. Effect of tissue factor pathway inhibitor (TFPI) in the Heptest assay and in amidolytic antifactor Xa assay for LMWH. Thromb Hemost 1992;68:310-314
13. Perrier D, Ashley JJ, Levy G. Effect of product inhibition on kinetic of drug elimination. J Pharmacokin Biopharm 1973:1:231-242
14. Estes J W. The kinetics of heparin. NY Acad Sei 1971 ; 179:187-204
15. McAvoy TJ. Pharmacokinetics modeling of heparin and its clinical implications. J Pharmacokin Biopharm 1979;4:331-354
16. Estes JW, Poulin PF. Pharmacokinetics of heparin: Distribution and elimination. Thromb Diath Haemorrh 1974;33:26-37
17. Perl W, Samuel P. Input-output analysis for total input rate and total traced mass of body cholesterol in man. Circ Res 1969;25:191-198
18. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokin Biopharm 1978:30:476-481
19. Cornell! U, Panucci A, Zingali G, et al. Pharmacokinetics of GM1 following parenteral administration. J Pharm Pharmacol 1990:42:708-711
20. Cutler DJ. Theory of the mean absorption time, an adjunct to conventional bioavailability studies. J Pharm Pharmacol I978;30: 476-480
21. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin, nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995:73:630-640
22. Erikson BI, S0derberg K, Widlund L, Wandeli B, Tengborn L. A comparative study of three low molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995:73:398-401
23. Frydman A. Low molecular weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996;26(Suppl 2):24-38
24. Frydman AM, Bara L, Le Roux M, et al. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single s.c. doses of 20 to 80 mg. J Clin Pharmacol 1988;28:609-618